Morgan Stanley Analysts Give GlaxoSmithKline plc (LON:GSK) a GBX 1,600 Price Target

GlaxoSmithKline plc (LON:GSK) received a GBX 1,600 ($21.11) price target from stock analysts at Morgan Stanley in a research note issued to investors on Wednesday, October 18th. The firm currently has a “sell” rating on the stock. Morgan Stanley’s target price points to a potential upside of 15.94% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Deutsche Bank AG reissued a “hold” rating and set a GBX 1,720 ($22.70) price target on shares of GlaxoSmithKline plc in a research report on Friday, June 30th. UBS AG set a GBX 1,600 ($21.11) price target on GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Wednesday, July 26th. Bryan, Garnier & Co reiterated a “neutral” rating and issued a GBX 1,710 ($22.57) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, September 19th. Credit Suisse Group reiterated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 21st. Finally, Citigroup Inc. lowered GlaxoSmithKline plc from a “buy” rating to a “neutral” rating and set a GBX 1,700 ($22.43) target price for the company. in a research report on Wednesday, July 5th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,657.14 ($21.87).

GlaxoSmithKline plc (LON GSK) traded down 0.69% during midday trading on Wednesday, hitting GBX 1370.50. 13,274,205 shares of the company traded hands. The stock has a 50 day moving average of GBX 1,495.28 and a 200 day moving average of GBX 1,574.67. The stock’s market cap is GBX 66.99 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,351.00 and a 12-month high of GBX 1,724.50.

GlaxoSmithKline plc (LON:GSK) last announced its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) earnings per share for the quarter, topping the Zacks’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%. Equities research analysts predict that GlaxoSmithKline plc will post $110.73 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/27/glaxosmithkline-plc-gsk-given-a-gbx-1600-price-target-at-morgan-stanley.html.

In other GlaxoSmithKline plc news, insider Urs Rohner bought 473 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average price of GBX 1,518 ($20.03) per share, for a total transaction of £7,180.14 ($9,474.98). Also, insider Simon Dingemans bought 1,076 shares of the business’s stock in a transaction dated Thursday, October 12th. The stock was acquired at an average price of GBX 1,527 ($20.15) per share, for a total transaction of £16,430.52 ($21,681.87). Insiders bought a total of 1,574 shares of company stock worth $2,398,888 in the last 90 days.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply